Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will make them no longer worthwhile for the company, according to CEO Vas Narasimhan.
#novartis #medicare #vasnarasimhan
Continue reading...